Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARγ-independent mechanism

Diabetologia

Volumn 48, Issue 3, 2005, Pages 586-594

  Artwohl, M ^a   Furnsinn C ^a   Waldhausl W ^a   Holzenbein T ^a   Rainer, G ^a   Freudenthaler, A ^a   Roden, M ^a,b   Baumgartner Parzer, S M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HANUSCH HOSPITAL   (Austria)

Author keywords

Mitochondrial mechanism; PPAR ; Proliferation; Thiazolidinediones; Vascular endothelial cells

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL] NICOTINIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; CYCLIN A; CYCLIN B; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; LACTIC ACID; NETOGLITAZONE; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RETINOBLASTOMA PROTEIN; RETINOID; ROSIGLITAZONE; ROTENONE; THYMIDINE; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL LINE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FETUS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MICROVASCULATURE; MITOCHONDRION; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA CELL; UMBILICAL VEIN; WESTERN BLOTTING;

ADULT; CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; MICROCIRCULATION; PERICYTES; PPAR GAMMA; RETINA; RETINAL VESSELS; THIAZOLIDINEDIONES; UMBILICAL VEINS;

EID: 16844379366     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1672-z     Document Type: Article

References (48)

1. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669
2. Brunmair B, Staniek K, Gras F et al (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059
3. Delerive P, Martin-Nizard F, Chinetti G et al (1999) Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85:394-402
4. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J (1999) PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19:546-551
5. Kato K, Satoh H, Endo Y et al (1999) Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 258:431-435
6. Jackson SM, Parhami F, Xi XP et al (1999) Peroxisome proliferator- activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19:2094-2104
7. Chen NG, Sarabia SF, Malloy PJ, Zhao XY, Feldmann D, Reaven GM (1999) PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression. Biochem Biophys Res Commun 263:718-722
8. Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116-9121
9. Panigrahy D, Singer S, Shen LQ et al (2002) PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923-932
10. Hsueh WA, Jackson S, Law RE (2001) Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care 24:392-397
11. Murata T, He S, Hangai M et al (2000) Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41:2309-2317
12. Murata T, Hata Y, Ishibashi T et al (2001) Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 119:709-717
13. Marx N, Mach F, Sauty A et al (2000) Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164:6503-6508
14. Wang M, Wise SC, Leff T, Su T-Z (1999) Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γ. Diabetes 48:254-260
15. Brunmair B, Gras F, Neschen S et al (2001) Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes 50:2309-2315
16. Reginato MJ, Bailey ST, Krakow SL et al (1998) A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 273:32679-32684
17. Artwohl M, Graier WF, Roden M et al (2003) Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes 52:1240-1247
18. Artwohl M, Roden M, Waldhäusl W, Freudenthaler A, Baumgartner-Parzer SM (2004) Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB J 18:146-148
19. Artwohl M, Roden M, Hölzenbein T, Freudenthaler A, Waldhäusl W, Baumgartner-Parzer SM (2002) Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obesity Relat Metab Disord 26:577-580
20. Grant MB, Guay C (1991) Plasminogen activator production by human retinal endothelial cells of non-diabetic and diabetic origin. Invest Ophthalmol Vis Sci 32:53-64
21. Nayak RC, Berman AB, George KL, Eisenbarth GS, King GL (1988) A monoclonal antibody (3G5)-defined ganglioside antigen is expressed on the surface of microvascular pericytes. J Exp Med 167:1003-1015
22. Bull AW, Steffensen KR, Leers J, Rafter JJ (2003) Activation of PPAR γ in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR γ. Carcinogenesis 24:1717-1722
23. + in alkaline hydrazine buffers: improved conditions for the assay of L-glutamate, L-lactate and other metabolites. Anal Biochem 88:475-484
24. de Dios ST, Bruemmer D, Dilley RJ et al (2003) Inhibitory activity of clinical thiazolidinediones peroxisome proliferator activating receptor-γ ligands toward internal mammary artery, radial artery and saphenous vein smooth muscle cell proliferation. Circulation 107:2548-2550
25. 1/S phase transition in fibroblasts. J Biol Chem 273:14958-14961
26. Sherr CJ (1995) D-type cyclins. Trends Biochem Sci 20:187-190
27. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD (1994) The cell-division cycle. In: Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD (eds) Molecular biology of the cell. Garland Publishing, New York, pp 863-910
28. 1/S-regulatory genes. Mol Cell Biol 15:4215-4224
29. Weinberg RA (1996) E2F and cell proliferation: a world turned upside down. Cell 85:457-459
30. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323-330
31. 1→S transition in vascular smooth muscle cells. J Biol Chem 275:22435-22441
32. WAF1/Cip1: more than a break to the cell cycle? Biochim Biophys Acta 1471:M43-M56
33. Auwerx J (1999) PPARγ, the ultimate thrifty gene. Diabetologia 42:1033-1049
34. Berger J, Bailey P, Biswas C et al (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195
35. Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405:421-424
36. Coates G, Nissim I, Battarbee H, Welbourne T (2002) Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells. Am J Physiol 283:E729-E737
37. Dello Russo C, Gavrilyuk V, Weinberg G et al (2003) Peroxisome proliferator-activated receptor γ thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278:5828-5836
38. 2 increase mitochondrial complex I activity in endothelial cells. Am J Physiol Heart Circ Physiol 285:H2298-H2308
39. Green K, Brand MD, Murphy MP (2004) Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53(Suppl 1):S110-S118
40. Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790
41. Spitaler MM, Graier WF (2002) Vascular targets of redox signalling in diabetes mellitus. Diabetologia 45:476-494
42. Fukunaga Y, Itoh H, Doi K et al (2001) Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158:113-119
43. Gilles PS, Dunn CJ (2000) Adis new drug profile - Pioglitazone. Drugs 60:333-343
44. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ (2003) Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46:1319-1323
45. Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman AJ (1997) Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 37:1114-1120
46. Boeri D, Maiello M, Lorenzi M (2001) Increased prevalence of microthrombosis in retinal capillaries of diabetic individuals. Diabetes 50:1432-1439
47. Ruderman NB, Cacicedo JM, Itani S et al (2003) Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial damage in diabetes. Biochem Soc Trans 31:202-206
48. Ruderman NB, Williamson JR, Brownlee M (1992) Glucose and diabetic vascular disease. FASEB J 6:2905-2914